India Pharma Outlook Team | Wednesday, 01 July 2026
The government of Telangana aims to initiate plans to collaborate with Pharmaceutical companies by introducing sufficient infrastructure for medicine and businesses in Hyderabad. This aims to turn Hyderabad into a destination that has significant value in the pharmaceutical supply chain.
This project is currently under discussion, with stakeholders like Nasscom and business technology bodies. Further, this project aims to bring together global and Indian pharmaceutical companies, global capability centres (GCC’s), research institutions, startups and investors to create a comprehensive ecosystem for pharmaceutical and commercialisation.
As per reports, Hyderabad already produces 40 per cent of India’s pharma production and a third of global vaccines. Therefore, the government brought out a new plan to shift from basic medicine production to high-value medicine innovation.
For instance, recently Swiss Pharma announced set its second digital tech hub in Hyderabad, which will go live in the first quarter of 2025. As the Chief Data Officer, Ramesh Durvasula says that Hyderabad is an exceptional destination for tapping into India’s vibrant healthcare and technology ecosystem.
This plan already includes integrating GCC’s, research institutions, and other pharmaceutical companies to expand the possibilities of growing into a major business hub. And collaboration with stakeholders such as Nasscom would help in commercialising the efficiency of drugs.
“IT and Industries Minister D. Sridhar Babu quotes that, we’re creating the conditions for the next generation therapies to be discovered, deployed, and delivered in Telangana.”
Also Read: Driving Vaccine Adoption Beyond Pediatric Immunization in India
Right after Telangana comes Karnataka, which is known to be a biotechnology and pharmaceutical innovation hub, particularly in Bengaluru. It is known to lead in research and development, biopharma, and is a host for specialised biotech parks for pharmaceutical companies.
Similarly, states like Maharashtra, Gujarat, Andhra Pradesh, Tamil Nadu, and Uttar Pradesh have bulk drug manufacturing companies that are involved in production, innovation and operate high- volume exports, and are also prominent pharma market hubs that continue to grow.
Hyderabad is already among the leading pharmaceutical hubs, established as a global life science powerhouse, which gives a strong foundation to expand into drug discovery and innovation. This includes clusters like Genome Valley, which is responsible for the production of a third of global vaccines.
Compared to other states, which are focused on conventional industrial policies, such as subsidies and large investments, Telangana is focused on reducing pricing and complexity in drug discovery, and thereby creating facilities that companies can access by boosting the current infrastructure.
This is in account to building partnerships with private companies, research institutions, and startups, thereby making it easy for them. Through creating infrastructure and funding, which is more logical compared to spending billions on government-initiated drug discovery.
As part of this project, the state is planning a 100-acre site for biologics, and another advanced therapy cluster in the 2,100 acres of Bharat Future City. And these will contribute to focusing on cell and gene therapies, biosimilars, and precision medicine.
Therefore, this project is likely to create investment of around USD 25 billion and will create almost 5 lakh job opportunities. It also aims to arrive at the top five life sciences clusters by 2030, in accordance with the new life science policy 2026-30.
.jpg)
